Enanta Pharmaceuticals Unternehmenskultur

Dr. Jay R. Luly, Ph.D, has been the Chief Executive Officer and President of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. He has over 20 years of experience in large pharma, mature biopharmaceutical and early-stage biotech environments. Previously he was employed at Oxford Bioscience Partners as an Entrepreneur in Residence. Dr. Luly served as Senior Vice President of R&D Operations and Senior Vice President of Discovery Strategy and Operations of Millennium Pharmaceuticals, following Millennium Pharmaceuticals, Inc. merger with LeukoSite, Inc., where he served as Senior Vice President of Drug Discovery and Pre-Clinical Development. Dr. Luly served as Vice President of Drug Discovery at LeukoSite, Inc. Prior to joining LeukoSite, he held a number of senior drug discovery positions at Abbott Laboratories from 1983 to 1997. His Research and development efforts have resulted in several therapeutics reaching clinical development and he is an inventor on 45 issued U.S. patents and has authored over 150 scientific publications, abstracts and review articles. Dr. Luly has been a Director of Enanta Pharmaceuticals, Inc. since July 2003. He served as a Director of Artesian Therapeutics, Inc. He serves as a Trustee of Boston Biomedical Research Institute, Inc. Dr. Luly earned a B.S. with highest distinction from University of Illinois, Urbana/Champaign and a Ph.D. in synthetic organic chemistry from University of California, Berkeley.

Dr. Yat Sun Or, Ph.D., has been the Chief Scientific Officer and Senior Vice President of Research & Development at Enanta Pharmaceuticals, Inc. since November 1999. Dr. Or served as Senior Project Leader of Anti-Bacterial Project at Abbott Laboratories from 1985 to 1999. Prior to Abbott, he served as Senior Scientist of Schering-Plough. He served as a Member of Advisory Board of Gloucester Pharmaceuticals, Inc. He holds over 30 U.S. Patents and has published 40 scientific papers and presentations in the areas of drug discovery and development. He earned his PhD in Organic Chemistry from the University of Chicago and completed Postdoctoral Fellowships at Ohio State University and Indiana University.

Dr. Timothy D. Ocain, also known as Tim, Ph.D., has been Senior Vice President of New Product Strategy and Development at Enanta Pharmaceuticals, Inc. since January 2014. Dr. Ocain serves as Advisor of Seaside Therapeutics LLC. Dr. Ocain serves as Consultant to companies in the pharmaceutical and biotechnology industries, where he has over twenty years of experience. Dr. Ocain held several leadership positions, including Senior Vice Presidentof Research and Development for Seaside Therapeutics from 2005 to 2009. Prior to Seaside, he served an eight-year tenure at Millennium Pharmaceuticals, most recently leading the Inflammation Disease Group, where he directed all pharmacology, cellular immunology and biochemistry efforts playing a principal role in the delivery of multiple compounds suitable for clinical development. Dr. Ocain has also held senior drug discovery positions with extensive project management responsibilities at Procept, Inc. where he served as Vice President, Chemistry and Structural Biology and at Wyeth-Ayerst Research where he engaged in cardiovascular, CNS and immunology drug discovery. Dr. Ocain has authored more than 20 peer-reviewed publications in basic research and drug discovery and holds more than 15 patents. Dr. Ocain received his Ph.D. in pharmaceutical chemistry from the University of Wisconsin-Madison and completed his post-doctoral research at the University of Minnesota.

Mr. Nathaniel S. Gardiner J.D., has been Senior Vice President and General Counsel of Enanta Pharmaceuticals, Inc. since May 2014 and its Secretary since 1995. Mr. Gardiner was a Partner and Co-Head for Business Law Department of Edwards Wildman Palmer LLP (also known as Edwards Angell Palmer & Dodge LLP). Mr. Gardiner serves as General Counsel to public and private life sciences and technology companies in a wide range of corporate matters, including public and private equity offerings and acquisitions, plus a variety of other business agreements and strategic and corporate governance matters. He served as Secretary of Dyax Corp. He was a Partner of Palmer & Dodge LLP. His areas of practice includes business law, public offerings and public company counseling, mergers & acquisitions, startup Companies and cross border. He typically focuses on the technology and life sciences sector. Mr. Gardiner has also advised U.S. clients on cross-border transactions involving companies in Germany, the Netherlands, Sweden and the United Kingdom and works with U.S. companies on matters involving their operations in other European Union countries, Canada, Latin America, Japan and elsewhere. He served as a Trustee of Joslin Diabetes Center, Inc. He has spoken on a numerous events and published articles. He is a member of the American Bar Association and Boston Bar Association. He is admitted to the Massachusetts Bar. Mr. Gardiner received a J.D. degree from the University of Virginia School of Law and an A.B. degree from the Harvard College.

Mr. Paul J. Mellett Jr., has been the Chief Financial Officer and Senior Vice President of Finance & Administration at Enanta Pharmaceuticals, Inc. since September 2003. Mr. Mellett serves as Principal Accounting Officer at Enanta Pharmaceuticals, Inc. Mr. Mellett joined Enanta in September 2003. He has over 25 years of financial experience. From April 2001 to August 2003, he served as the Senior Vice President, Chief Financial Officer and Assistant Secretary of Trine Pharmaceuticals Inc. (formerly, Essential Therapeutics Inc., a publicly-held biotechnology company). He served as the Vice President and Chief Financial Officer of Althexis since April 2001. From 1997 to 2000, he served as the Chief Financial Officer and Vice President, Administration & Finance at GelTex Pharmaceuticals Inc., a company which releases and develops non-absorbed polymer drugs and was acquired by Genzyme Corporation in December 2000. He also served as the Principal Accounting Officer and Treasurer of GelTex Pharmaceuticals Inc. From 1994 to 1997, he served as the Chief Financial Officer of Marshall Contractors, a construction management firm specializing in the pharmaceutical/biotechnology and semiconductor industries, which was acquired by Fluor Corporation in 1996. From 1977 to 1994, he was employed with Deloitte & Touche LLP, a public accounting firm and was an Audit Partner since 1989. He is a Director of Caritas Norwood Hospital and Big Brother Association of Massachusetts Bay. Mr. Mellett received a BS in Business Administration from Boston College.

Nathaniel Gardiner serves as the Senior Vice President and General Counsel of Enanta Pharmaceuticals. Nathaniel started at Enanta Pharmaceuticals in May of 2014. Nathaniel currently resides in the Greater Boston Area.

Lijuan Jiang serves as the Executive Director of DMPK and Bioanalysis of Enanta Pharmaceuticals. Lijuan started at Enanta Pharmaceuticals in May of 2004. Lijuan currently resides in the Greater Boston Area.

Matthew Ronsheim serves as the Executive Director, Head of CMC of Enanta Pharmaceuticals. Matthew started at Enanta Pharmaceuticals in Dec of 2017. Matthew currently resides in the Greater Boston Area.